Details of the Drug Combination

General Information of Drug Combination (ID: DC1BJAR)

Drug Combination Name
Merimepodib Remdesivir
Indication
Disease Entry Status REF
COVID-19 Phase 2 [1]
Component Drugs Merimepodib   DM0HS92 Remdesivir   DMBFZ6L
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Merimepodib
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Gastric adenocarcinoma 2B72 Phase 3 [2]
Hepatitis C virus infection 1E51.1 Phase 2b [3]
Head and neck cancer 2D42 Phase 2 [2]
Hepatitis virus infection 1E50-1E51 Discontinued in Phase 2 [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [5]
Merimepodib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [9]
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) TTL7C8Q IMDH1_HUMAN Inhibitor [10]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [9]
HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) TTTU6X1 IMDH2_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Remdesivir
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Approved [6]
Ebola virus infection 1D60.0 Phase 1 [7]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [8]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [8]
Remdesivir Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
MERS-CoV RNA-directed RNA polymerase (RdRp) TTOA6YT R1AB_CVEMC (4378-5310) Inhibitor [8]
SARS-CoV RNA-directed RNA polymerase (RdRp) TTKXI53 R1AB_CVHSA (4370-5301) Inhibitor [8]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [11]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [6]
------------------------------------------------------------------------------------
Remdesivir Interacts with 14 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [12]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Increases Expression [12]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Expression [12]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [12]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [12]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [12]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [12]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Decreases Expression [12]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [12]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Phosphorylation [12]
Lysosomal protective protein (CTSA) OT167UBM PPGB_HUMAN Increases Hydrolysis [13]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Increases Hydrolysis [13]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases Hydrolysis [13]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Increases Hydrolysis [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DOT(s)

References

1 ClinicalTrials.gov (NCT04410354) Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
3 Merimepodib, Pegylated Interferon, and Ribavirin in Genotype 1 Chronic Hepatitis C Pegylated Interferon and Ribavirin Nonresponders. Hepatology. 2009 Dec;50(6):1719-26.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008158)
5 The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. April 09, 2020. doi: https://doi.org/10.1101/2020.04.07.028589
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10 VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
11 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
12 An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
13 Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans. Chem Biol Interact. 2022 Jan 5;351:109744. doi: 10.1016/j.cbi.2021.109744. Epub 2021 Nov 11.